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Abstract 
 
Aims: Aggressive epidermotropic cutaneous CD8+ lymphoma is currently afforded 
provisional status in the WHO classification of lymphomas.  An EORTC Workshop was 
convened to describe in detail the features of this putative neoplasm and evaluate its 
nosological status with respect to other cutaneous CD8+ lymphomas. 
 
Methods & Results: Sixty-one CD8+ cases were analysed at the workshop; clinical details, 
often with photographs, histological sections, immunohistochemical results, treatment and 
patient outcome were discussed & recorded.  Eighteen cases had distinct features and 
conformed to the diagnosis of aggressive epidermotropic cutaneous CD8+ lymphoma.  The 
patients typically present with widespread plaques and tumours, often ulcerated and 
haemorrhagic, and have striking pagetoid epidermotropism histologically. A CD8+ 
CD45RA+ CD45RO- CD2- CD5- CD56- phenotype, with 1 or more cytotoxic markers was 
found in 7/18 with a very similar phenotype in the remainder.. The tumours seldom involve 
lymph nodes but mucosae and central nervous system involvement are not uncommon. The 
prognosis is poor, with a median survival of 12 months. Examples of CD8+ mycosis 
fungoides, lymphomatoid papulosis and Woringer-Kolopp presented the typical features well 
documented in the CD4+ forms of those diseases.   
 
Conclusions: Aggressive Epidermotropic Cutaneous CD8+ Lymphoma is a distinct 
lymphoma that warrants inclusion as a distinct entity in future revisions of lymphoma 
classifications. 
 
Aggressive Epidermotropic Cutaneous CD8+ Lymphoma: A 
cutaneous lymphoma with distinct clinical and pathological 
features. 
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Background: The recent WHO-EORTC consensus classification on cutaneous lymphomas 
included aggressive epidermotropic CD8+ lymphoma (as originally described by Berti et al) 
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under the “provisional” category. This reflects the paucity of published data with respect to 
this lymphoma & whether it warrants recognition as a discrete clinico-pathological entity. 
 
Methods: This study collected 71 cases of CD8+ cutaneous lymphoma. The cases were 
collected for a workshop of the European Organisation for Research and Treatment of Cancer 
Cutaneous Lymphoma Task Force (EORTC), convened in London, specifically to assess the 
nosological status of aggressive cutaneous epidermotropic CD8+ lymphoma, and formally 
assess the clinicopathological features of the CD8 variants of the more common forms of 
cutaneous T-cell lymphoma.  
 
Results: Of 71 cases, 61 were included in the study. These comprised 18 cases of aggressive 
cutaneous epidermotropic CD8+ lymphoma, 34 examples of CD8+ mycosis fungoides, 6 
cases of CD8+ lymphomatoid papulosis, 2 of solitary pagetoid reticulosis (Woringer-Kolopp) 
and 1 borderline LyP – anaplastic large cell lymphoma. Patients with aggressive cutaneous 
epidermotropic CD8+ lymphoma presented with widespread ulcerated plaques and tumours, 
often haemorrhagic, or in some examples, 2-3 large ulcerated tumours. No patient had a 
history of patches and plaques, poikiloderma or other characteristic feature suggestive of 
mycosis fungoides. The median survival of this group is 12 months (cf CD8+ mycosis 
fungoides group, 31 remain alive with or without disease; p < 0.002). The tumour cells had a 
CD2- CD5- CD45RA+ CD45RO- phenotype in 7 cases, with many more cases varying from 
this phenotype in just 1 parameter; none labelled with CD56, and there was a proliferative 
fraction >50% in the 13 of the 18 cases so investigated. CD8+ mycosis fungoides, 
lymphomatoid papulosis and pagetoid reticulosis did not differ from the usual CD4+ 
diseases.  
 
Conclusion: Mycosis fungoides and lymphomatoid papulosis with a CD8+ phenotype do not 
differ from the usual CD4+ forms of the diseases. Aggressive cutaneous epidermotropic 
CD8+ lymphoma has a characteristic clinical presentation, pathology and prognosis, and is 
distinct from both classical and CD8+ cases of mycosis fungoides. This justifies its inclusion 
as a discrete sub-category of cutaneous lymphoma in future revisions of the consensus 
classification. 
 
Introduction 
 
There has been consensus in the classification of cutaneous lymphoma culminating in the 
publication of the WHO lymphoma classification with its distinct section of cutaneous 
lymphomas¹. This document acknowledges the completely different clinical behaviour and 
prognosis of many primary cutaneous lymphomas when compared to their counterparts 
arising at other sites. 
 While there remains little controversy with respect to mycosis fungoides, Sezary 
syndrome and primary cutaneous CD30+ lymphoproliferations, the remaining group of 
diseases, constituting < 10% of cutaneous lymphomas, are more problematic. In particular, a 
provisional category has been retained for two putative entities, viz. Primary cutaneous CD4+ 
small/medium pleomorphic T-cell lymphoma & primary cutaneous aggressive CD8+ T-cell 
lymphoma. Although there is presumptive evidence to support the inclusion of these as bona 
fide categories, it has been concluded that more data are required before granting each 
unequivocal status as a clinico-pathological entity distinct from other forms of cutaneous 
lymphoma. A meeting of the EORTC was convened in London, in which cases of primary 
cutaneous CD8+ lymphoma were assembled from many centres across Europe, discussed 
and, more specifically, the potential status of primary cutaneous aggressive CD8+ T-cell 
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lymphoma as a disease entity considered. The findings of the conference indicate this 
lymphoma has distinct clinical, pathological and immunophenotypic features thus supporting 
the inclusion of this lymphoma as a separate category in future revisions of the consensus 
classification. 
 
Material and Methods 
Cases 
 
A total of 71 examples of CD8+ lymphoma were submitted for inclusion in the study by the 
members of the EORTC Cutaneous Lymphoma Task Force. The following data were 
recorded: sex, age at diagnosis, site of manifestation, clinical presentation, involvement of 
other organs, therapy, length of follow-up and outcome.  
Juvenile CD8+ hypopigmented mycosis fungoides has been the subject of several 
publications, is widely acknowledged as a particular variant of T-cell lymphoma, and no 
cases were submitted for consideration. Furthermore, subcutaneous T-cell lymphoma was 
actively excluded as this disease formed the basis of a separate workshop. 
 
Pathology Studies 
All biopsy specimens were routinely processed and embedded in paraffin. According to 
available material, 5μm tissue sections were cut and stained with haematoxylin and eosin, 
and by immunohistochemistry for the antibodies listed in Table 1. Expression by >75% of 
cells was defined as positive, <10% negative, 10-75% +/-.  
 
Table 1. Antibodies used for immunophenotyping. 
The cases were reviewed and classified by attending pathologists and dermatologists in 
discussion in a lecture theatre and around a multiheaded microscope. A consensus was 
defined as no individual author dissented. 
 
Statistical Analysis 
Survival time was calculated from the date of histologically confirmed diagnosis until the 
lymphoma-related death or latest known follow-up using SAS 9.2 statistical package. The 
cut-off level for statistical significance was set at 0.05 in all analyses. 
 
Results 
Definition of Groups 
 
Based on the collected clinical, histological and immunohistochemical data three principal 
groups were defined. The majority of cases (34) could be classified as CD8+ mycosis 
fungoides; there were 6 cases of CD8+ lymphomatoid papulosis, 1 of CD8+ lymphomatoid 
papulosis - cutaneous anaplastic large cell lymphoma overlap and 2 cases of pagetoid 
reticulosis. Eighteen cases were distinct from these groups and matched the previous 
descriptions of primary cutaneous aggressive CD8+ T-cell lymphoma.  Ten cases were 
rejected from the study. These were as follows: three cases were either deemed unclassifiable 
(primary cutaneous T-cell lymphoma NOS according to the EORTC –WHO consensus 
classification, e.g. an unusual double CD4+ /CD8+ lymphoma arising in an HIV+ patient) or 
formed isolated sundry albeit well-recognised diseases - HTLV-1+ CD8+ lymphoma and 
CD8+ ATLL. Seven further cases had insufficient details supplied for inclusion; all these 
were rejected & took no further part in the study. 
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Mycosis fungoides  (MF) with CD8 phenotype 
This group constituted the majority of submitted cases, 20 males and 14 females with a mean 
age of 49.6 years (males 53, females 46.3 years) (Table 2). A crucial feature of this group 
was the clinical presentation of patches and plaques typical of classical mycosis fungoides 
(Figs 1a-c & 1d). The distribution of disease did not differ from classical CD4+ MF.  
 
Table 2 Cases of Mycosis fungoides, Lymphomatoid papulosis and Pagetoid Reticulosis 
with a CD8+ phenotype 
 
Figs. 1a, b & c. Three examples of patients with patches of CD8+ mycosis fungoides, 
indistinguishable from classical CD4+ disease.   
 
Fig. 1d. A plaque of CD8+ mycosis fungoides on the lower limb. 
 
Fig. 1e. Tagging of lymphocytes with perinuclear halos along the basal epidermal layer, 
in a case of mycosis fungoides (H&E x200). 
 
The cases presented the histomorphology usually associated with, and well-
documented in, classical MF. Thus, epidermotropism, tagging along the basal epidermal layer 
(Fig. 1e), Pautrier microabscesses, variable dermal infiltrate of pleomorphic cells having 
cerebriform nuclear contours were each seen to varying degrees in this group. The dermal 
infiltrate varied in accord with patch, plaque or tumour stage of disease. No features appeared 
to distinguish the group from commonplace CD4+ MF.  
By definition a majority of tumour cells expressed CD8 (Fig 1f); all failed to react with the 
CD4 antibody. The majority of cases labelled with one or both of granzyme B and TIA-1. A 
single case expressed CD56. In 23 cases of CD8+ MF so tested 18 were CD45RO+. Of 15 
tested all expressed CD2, whilst of 16 tested 11 labelled with CD5. Ki-67 was assessed in 19 
and revealed a low proliferative fraction (10- <50%) in all. 
Similarly, following  a variety of accepted treatment regimens commonly used in 
mycosis fungoides survival time mirrored the more common CD4 form of the disease (Fig. 
1g); all but two patients are still alive, having received a variety of standard therapies after a 
median of 47 months. Treatments included; PUVA, UVB, topical steroids, nitrogen mustard, 
radiotherapy, methotrexate, miltefosine, cyclophosphamide, gemcitabine, alpha-interferon, 
bexarotene, TSEB & CHOP.  
 
Fig. 1g. Survival curves of patients with CD8+ mycosis fungoides & aggressive 
epidermotropic CD8+ lymphoma 
 
Lymphomatoid Papulosis.  
 
These 6 patients presented with groups of ulcerating papules and nodules, which 
characteristically waxed and waned, in the typical manner of LyP (Table 2). In two cases the 
lesions had a haemorrhagic appearance, but otherwise did not differ appreciably from 
classical LyP. All patients followed a benign clinical course, having been treated with 
standard therapeutic regimens, which included simple follow up, PUVA & methotrexate. 
 
Histologically, a wedge-shaped infiltrate with a mixed population of cells, including 
large atypical mononuclear CD30+ cells, was seen in 4 cases, with a further case having 
sheets of anaplastic cells typifying type C. In a single case the infiltrate comprised smaller 
CD30- cells akin to those seen in MF, typical of LyP type B. One additional case was 
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classified as LyP/ALCL overlap, and presented as a solitary nodule, which regressed. 
Histologically there was a dense population of CD30+ CD8+ T-cells with relatively few 
admixed inflammatory cells. The patient remains well. None of the cases conformed to the 
recently described lymphomatoid papulosis type D, in which the CD8+ lesional cells 
infiltrate the epidermis with a pagetoid reticulosis pattern. 
 
Solitary pagetoid reticulosis (Woringer-Kolopp) 
 
Two patients presented with solitary hyperkeratotic erythematous patches characteristic of 
the solitary form of pagetoid reticulosis, a recognised variant of MF. Histologically, there 
was marked pagetoid epidermotropism of medium-sized atypical mononuclear T-cells. 
Neither patient has progressive disease, with each responding to local directed therapy, UVB 
and steroids (Table 2). 
 
Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma 
 
 In 18 cases there was consensus that the lymphoma differed substantially from cases 
included in the previous groups. The clinical details of this group of patients are summarised 
in Table 3a. These patients were mainly adult with 11 males & 7 females, and a mean age of 
54.5 years (males 51.6, females 59.4; range 27-87). The clinical presentation not only 
differed from usual MF, lacking the patches and plaques that define that disease, but 
displayed lesions that had many similar features. Lesions were located in multiple sites 
including the trunk, arms and legs, and face. Mucosal (oral) disease was noted at presentation 
in 2 cases. Ulcerated crusted and nodular lesions were most common, often with 
haemorrhagic foci. Infiltrated plaques or tumours manifest early in the disease (Figs. 2a-g); 
Clinical follicular involvement was not a feature commented upon in any case. In two 
patients a limited number of tumours, particularly on the face, led to the patient presenting 
(Fig. 2h). No patient gave a long history of scaly patches or poikiloderma to suggest an 
evolution from a more indolent prodromal period. One patient had a history of rheumatic 
fever and a clinical diagnosis of vasculitis was initially made. Staging procedures, in 17 
patients, including chest X-rays, abdominal, chest and total body CT scans, revealed enlarged 
lymph nodes in only one instance at presentation, found to be reactive on biopsy, confirming 
the lesions to be primary cutaneous. Bone marrow investigations in all patients failed to 
reveal involvement by disease. In 13 cases the patients rapidly succumbed to the disease, 
with a median survival of 12 months. A variety of therapies had been used in these patients; 
13 patients underwent chemotherapy or immunotherapy, with or without radiotherapy or 
PUVA. While a few patients enjoyed a partial response, only 1 had a complete response 
recorded, who then subsequently relapsed and died. Two patients underwent autopsy 
examinations: in one, no evidence of visceral disease was found; the other had widespread 
involvement of liver, lungs, spleen, heart and mediastina lymph nodes. HIV status was 
negative in the 10 patients investigated; HTLV-1 status was assessed in 4 and was negative. 
Survival differed significantly from the MF group, with a median survival of 12 months  (p < 
0.002) (Fig 1g). 
 
Table 3a Primary Cutaneous Aggressive Epidermotropic CD8+ Lymphoma 
 
Figs. 2a-g. Presentations of aggressive epidermotropic CD8+ lymphoma included 
widespread ulcerated plaques and tumours,  a) often haemorrhagic; b) haemorrhagic 
plaques on the chest and trunk & limbs of these patients:  c) ulcerated tumours & 
plaques (same patient as “a”: d) deeply ulcerated tumour: e) Disseminated ulcerated 
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haemorrhagic plaques. This patient had no visceral disease at autopsy; f) haemorrhagic 
necrotic plaques: g) Ulcerated tumours on the head and trunk. 
 
Fig. 2h. Aggressive epidermotropic CD8+ lymphoma; a solitary periorbital mass, 
clinically mimicking extranodal NK/T-cell lymphoma and blastic plasmacytoid 
dendritic cell neoplasm.  
 
Biopsies had been taken from a variety of clinical lesions, and this was reflected in the 
histology. Thus, ulceration was common, being observed in 14 patients. Erythematous 
hyperkeratotic plaques typically revealed hyperkeratosis and/or acanthosis, and striking 
epidermotropism. The epidermotropism was a conspicuous observation in 15 cases, 
conforming to a pagetoid reticulosis pattern i.e. single atypical cells liberally replacing the 
epidermis albeit most concentrated in the lower portion (Fig 3a-d). Pautrier microabscesses 
were conspicuously lacking despite the number of malignant cells, only being noted in two 
cases, and then a minority feature; similarly, lining of atypical cells along the epidermal basal 
layer – “tagging” - was never an observation; the epidermis was simply liberally peppered by 
individual atypical cells akin to that seen in solitary and diffuse forms of pagetoid reticulosis. 
Folliculotropism was noted in 8 cases of 11 in which follicles were well seen (Figs. 4a &b), 
with a similar pattern of single cell infiltration, albeit often florid, but mucinous degeneration 
of follicles was absent, and follicular disease was in all cases overshadowed by the interstitial 
and epidermal infiltrate; malignant cells permeated between eccrine glands in 5 cases of 8 in 
which these were clearly visualised but syringotropism proper was not convincing, present 
focally in a single case (Figs. 5a &b). A diffuse and dense dermal population of pleomorphic 
cells was found in biopsies of the clinical tumours. Angiocentricity was a common finding 
(Figs. 6a-d), observed in 11 biopsies, sometimes accompanied by angiodestruction. 
Ischaemic necrosis within the dermis was pronounced in 2 cases and ischaemic necrosis of 
the epidermis in 5. The dermal infiltrate consisted of medium-sized but quite monotonous 
atypical cells in the vast majority of cases. The majority of cells in most cases had enlarged 
hyperchromatic rounded nuclei frequently with a coarse chromatin pattern (Fig.7). The 
cerebriform nuclear contour, the hallmark of MF, was not present in the majority of cells in 
any case, although perinuclear halos were often seen. Nodular collections of large highly 
pleomorphic/anaplastic cells that characterise “high grade” transformation in MF were not 
seen in any case. 
 
Figs. 3a-d. A pagetoid reticulosis pattern of epidermotropsim was characteristic of 
aggressive epidermotropic CD8+ lymphoma, without Pautrier microabscesses in the 
vast majority of biopsies (H&E, x200) 
 
Figs. 4a & b. Histological folliculotropism was common, although clinical follicular 
disease was not conspicuous clinically (H&E, x 200). 
 
Figs. 5a & b. Permeation of sweat glands was often seen (a) but convincing 
syringotropism proper only found focally in one case (b) (H&E x 200). 
 
Figs. 6a-d. Ischaemic changes, including epidermal (a) and dermal (b) necrosis reflected 
the common finding of angiocentricity (d), sometimes with vasculitis/angiodestruction 
(d) (H&E, x100, x200, x40, x200 respectively). 
 
Fig. 7 Tumour cells of aggressive epidermotropic CD8+ lymphoma were mostly medium 
sized, and whilst markedly atypical, never large or blastic (H&E, a x200, b x400). 
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A variable interstitial component, and occasional subcutaneous extension, without adipocyte 
rimming, were other unremarkable sundry observations.  
The results of immunophenotyping these cases are presented in Table 3b. Several 
characteristic traits emerged within this group. Most (14) cases lacked CD2 and/or CD5, and 
expressed CD45RA (14 cases, Figs. 8a-d). Conversely, only 3 of 17 presented a population of 
cells that labelled with antibody to CD45RO, and in these few cells were positive. Of 10 
cases investigated for Beta-F1 expression, 8 were positive in the tumour cells. A high 
proliferative fraction with Ki-67 was found in all but 2 cases investigated. The neoplastic 
cells in each case expressed one or both of TIA-1 or granzyme B; none expressed CD30 or 
CD56. All tumours were negative with in-situ hybridisation for EBER. 
 
Table 3b Immunophenotype of Primary Cutaneous Aggressive Epidermotropic CD8+ 
Lymphoma cases* 
 
Figs 8a-d. Immunocytochemistry in cutaneous aggressive epidermotropic CD8+ 
lymphoma: a) diffuse expression of CD8 b) CD45RA and c) loss of CD5 expression.: d) 
a high proliferative fraction with Ki-67 was characteristic (x100). 
 
Discussion. 
 
The literature reports of “CD8+ lymphomas” suggest a markedly variable patient 
outcome. Agnarsson et al divided CD8+ lymphomas into progressive and indolent groups. 
The former presented with infiltrated plaques and nodules, the latter had chronic patches 
typical of mycosis fungoides (2). Other authors emphasise, either the aggressive nature of 
CD8+ lymphoma (3,4), a benign clinical course and/or that CD8 expression by neoplastic 
cells cannot be assumed to impart a poor prognosis (5, 6,7,49, 61). Hagiwara et al studied a 
series of CD8+ epidermotropic lymphomas and found spontaneous regression in 80% with 
only 1 fatality of 5 patients (8). However, little clinical description was provided, and the 
possibility of lymphomatoid papulosis types D & E (31; see below) not considered. 
 
Recent classifications of primary cutaneous lymphomas have emphasised the 
collective importance of clinical, pathological and immunophenotypic parameters in 
delineating disease entities. Mycosis fungoides, lymphomatoid papulosis and CD30 
lymphoproliferation, the most common T-cell lymphoid neoplasms, have well-established 
clinical features and pathological morphologies. There remain a group of rarer malignancies 
in which a paucity of data has undermined attempts to definitively assess nosological status 
and clinicopathological details. In 1999, Berti et al reported a series of 17 patients with 
cytotoxic lymphoproliferative disorders, variably characterised as lymphomatoid papulosis, 
anaplastic large cell lymphoma, mycosis fungoides and cases of a hitherto unreported 
aggressive epidermotropic form of CD8+ disease (9). These latter cases differed from the 
more common mycosis fungoides clinically and histopathologically. Since then there have 
been a number of isolated reports that attest to this distinctive entity (10, 11,12, 13, 14, 15, 
16, 50). It is accepted that MF, LyP and anaplastic large cell lymphoma may, exceptionally, 
display a cytotoxic phenotype. In such cases successful diagnosis rests on careful clinical and 
histological appraisal; thus, these diseases present the “usual” clinical and histological 
features of these disorders and simply differ in the cytotoxic phenotype of the neoplastic 
cells. Nevertheless, formal evaluation of these variants and comparisons with the 
provisionally accepted aggressive epidermotropic cytotoxic lymphoma of Berti has been 
wanting.  
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 In this paper, the clinical, histological and immunphenotypic characteristics of forms 
of CD8+ cutaneous lymphoproliferative disease have been collected and analysed. These 
proliferations encompass mycosis fungoides, lymphomatoid papulosis, anaplastic large cell 
lymphoma, Woringer-Kolopp and the provisional entity aggressive epidermotropic cytotoxic 
lymphoma.  
 
Of the cases submitted, 34 had the classic clinical phenotype of mycosis fungoides (MF). 
Thus, nothing in the presentation and clinical appraisal distinguished these patients from 
commonplace CD4 disease. Indeed, the first and only unusual characteristic was the finding 
of a CD8 immunophenotype on biopsy material. The other immunocytochemical findings 
were largely unextraordinary; a single case was CD56+, and the observation of T-cell antigen 
loss, when observed, did not conform to a particular pattern. MF is believed to represent a 
neoplasm of memory T-cells, reflected in the usual immunoexpression of CD45RO by the 
malignant cells. This contrasts with “native” CD45RO- but CD45RA+ T-cells. In the limited 
previous formal studies, < 9% of MF cases display immunopositivity for this marker (17); a 
higher fraction was observed in this series - 5 of 23 labelled with CD45RA. Most patients in 
the study group followed a protracted, relatively benign, course in accord with classical CD4 
MF. The findings herein convincingly indicate CD8+ MF to be indistinguishable from the 
usual CD4+ form of disease, differing only in the single immunphenotypic anomaly; 
furthermore, they are in agreement with previous authors who contend that CD8 expression, 
in and of itself, cannot be taken to imply a poor prognosis. (18, 6, 19), 20, 21, 22, 23, 24). 
The same assertion has been made with regard to the CD4- CD8- variant of otherwise typical 
MF (25) and CD56+ disease (51). Thus, careful clinical assessment for characteristic patches 
& plaques, or other hallmarks of MF e.g. follicular mucinosis, hypopigmentation or 
poikiloderma, are of critical importance for accurate diagnosis. 
 
 Similar observations obtain with respect to CD8+ variant lymphomatoid papulosis 
(LyP), cutaneous anaplastic large cell lymphoma (ALCL) and the solitary form of pagetoid 
reticulosis (Woringer-Kolopp). Interestingly, the presence of haemorrhagic lesions was 
commented upon in several cases. A characteristic wedge-shaped infiltrate of ulcerated skin, 
containing markedly atypical CD30+ T-cells completed an almost identical picture to 
classical LyP. The clinical observation of haemorrhage was reflected in evidence of this 
histologically. All patients remain alive and well in accord with the benign prognosis of 
typical LyP, and the reports of previous examples of CD8 LyP (26, 27).  Previous literature 
reports attest to the similarity of the CD8+ form of primary cutaneous ALCL to the classical 
CD4 disease, including the favourable prognosis (28, 27, 29, 30, 52). Lymphomatoid 
papulosis type D is a relatively recently distinct form of LyP (31), clinically identical to other 
forms of LyP, but distinctive in the pagetoid reticulosis pattern of epidermotropism and 
CD8+ phenotype.  Similarly, LyP type E commonly has a CD8+ phenotype, and displays an 
angiocentric histology (62). Thus, the differential diagnosis of these forms of LyP include 
aggressive epidermotropic CD8+ lymphoma; distinction between these two requires attention 
to clinical details and the presence or absence of CD30+ atypical cells. None of the cases of 
LyP in this series was of this type; furthermore, no patient in the aggressive CD8+ 
epidermotropic lymphoma group had a clinical history of waxing and waning papules or 
nodules to indicate associated LyP of any form, nor did they express CD30.  
The clinical appearance of the solitary form of pagetoid reticulosis, Woringer-Kolopp, 
accounted for 2 cases submitted. Approximately half of reported cases of pagetoid reticulosis 
are CD8+ (33, 53). The clinical observations of solitary scaly erythematous acral plaques, the 
striking histological epidermotropism are typical, and the disease did not progress in either 
patient.  
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 The remaining 18 cases of CD8+ lymphoma did not conform to mycosis fungoides, 
lymphomatoid papulosis or pagetoid reticulosis. Nevertheless, they were distinctive 
clinically, histologically and immunophenotypically. Of the 18 cases, 16 patients initially 
presented with widespread, often haemorrhagic plaques and extensive tumours.  
 
Immunohistochemically, all cases had a CD8+ CD4 - EBV - CD56 – phenotype. 
There is a suggestion of a CD2- CD5- CD45RO- CD45RA+ phenotype, this collective 
pattern being observed in 7 cases. In the physiological transition from naïve (CD45RA+) to 
memory (CD45RO+) T-cells there is up-regulation of the adhesion molecule, CD2, and 
therefore a relationship between the expressions of these immuno-markers may be expected.  
Agnarrson was the first to suggest that loss of CD2 expression correlates with a poor 
prognosis, but this is likely to reflect that such cases in that series were genuine aggressive 
epidermotropic CD8+ lymphoma, as opposed to the “chronic form” of CD8+ lymphoma viz. 
mycosis fungoides (2). Although neoplastic cells in MF are typically memory T-cells, and 
therefore CD45RO+ CD45RA-, the latter can be seen in a small minority of cases (the vast 
majority of which are CD4+), without an adverse prognosis in the few studied (17). Indeed, 
the switch between CD45RA and RO is not irreversible, particularly in the absence of 
continual antigen stimulation. (54). A markedly high proliferative fraction was reflected in at 
least 50%, often >75%, of malignant cells labelling with MIB-1 (to Ki-67 antigen) in 13 of 
17 so investigated, a feature uncommon in tumour MF unless transformation has supervened. 
This has been noted previously (11,12,13). 
 
 The basis for this aggressive behaviour remains speculative. Urosevic et al postulate that the 
expression of HLA-G, a non-classical HLA class Ib molecule restricted to immunoprivileged 
sites, may act to down-regulate the host natural anti-tumour response resulting in rapid 
evolution of disease. They found expression of this molecule in all four cases of CD8+ 
lymphoma tested (35). Nevertheless, the variability of prognosis between different forms of 
CD8+ lymphoma e.g. in comparison to juvenile hypopigmented MF, emphasise the situation 
is, perhaps, more complex (6, 18, 19). 
 
 These cases are distinct from known and accepted forms of cutaneous lymphoma. 
One proffered interpretation is that these tumours represent an aggressive form of mycosis 
fungoides. However, the cases of CD8+ MF in this series, and others, convincingly 
demonstrate that clinically typical CD8+ MF follows a natural course of progression identical 
to the commonplace CD4+ disease (24). 
 
Furthermore, the relatively short history of widespread ulcerated haemorrhagic 
nodules and tumours is not the usual clinical presentation of MF, but invites a different 
differential diagnosis, including cutaneous γδ lymphoma and Ketron-Goodman disease. Most 
circulating T-cells express the αβ chain in the T-cell receptor with < 5% of the γδ subtype. 
The latter are the neoplastic cell in the aggressive γδ lymphoma, which may present a clinical 
picture very similar to primary cutaneous CD8+ lymphoma, and has a similarly dismal 
prognosis. Cutaneous γδ lymphoma, however, has a CD4- CD8- CD56+ immunophenotype 
in the vast majority of instances (37); moreover, by definition, the malignant cells will be 
negative for the beta chain of the T-cell receptor. Although two of the cases in this series 
were also negative for beta-F1, this does not prove that the malignant T-cells were of γδ type, 
as the antigen may simply fail to be expressed. In both cases the malignant cells had a CD8+ 
CD56- phenotype, which is not that typically seen in γδ lymphomas. Furthermore, a frozen 
section of one of these tumours was also negative for T-cell receptor δ. Nevertheless, 
although in the majority of cases the tumour cells of γδ lymphomas are CD8-, a small 
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physiological population of CD4- CD8+ γδ T-cells is known to exist (38, 55). The possibility 
that some cases of primary cutaneous CD8+ lymphoma are a rare form of γδ cutaneous 
lymphoma can not always be excluded; nevertheless, most examples of γδ lymphoma are 
CD56+, not seen in any of our cases, and immunolabelling for beta-F1 excludes those tested 
in our series.  
 
A few case reports do suggest that in rare cases, this aggressive lymphoma can be 
preceded by a lengthy prodromal period (39, 40), although in Ito et al the histology of the 
original lesions dating 10 years previously had not been presented or discussed; moreover, 
the relationship of the lymphoma to the long history of psoriasis in Weenig et al is uncertain.  
At least one case has been linked to HTLV-1 infection, (41) although the authors’ did not 
demonstrate viral integration into neoplastic cells. Finally, a single case with anomalous 
expression of CD15 has been reported (42). Interestingly, the possibility of therapy inducing 
a CD8+ lymphoma, or worsening prognosis in this lymphoma, has been postulated by several 
authors (14, 56) & attributed to augmentation of Th1 immunity. 
 
Previous reports by some of the authors (1,9) have indicated the difficulties in making 
the distinction between aggressive epidermotropic CD8+ lymphoma and other forms of 
CD8+ T-cell lymphoma. However, the analysis of this large series indicates that other 
recognisable forms of CD8+ T-cell lymphoma present diagnostic histological features not 
seen in any of these cases eg CD30 expression in lymphomatoid papulosis & anaplastic 
lymphoma. Conversely, unlike MF, there are few or no Pautrier microabscesses despite 
considerable epidermotropism, there is a pagetoid reticulosis pattern of epidermotropism and 
the neoplastic cytology is more monotonous than is usual in MF. Finally, 
immunhistochemistry suggests distinct phenotypes. 
 
Patients with the disseminated form of pagetoid reticulosis (Ketron-Goodman disease) 
present with multiple ulcerated plaques and tumours at various sites, similar to patients in our 
series, and often have a poor prognosis (43, 44, 45). It is likely that many patients diagnosed 
with disseminated pagetoid reticulosis have either aggressive epidermotropic CD8+ or 
cutaneous γδ lymphoma; a minority may represent rare examples of aggressive MF. Previous 
reports of  disseminated pagetoid reticulosis detail variable phenotypes, including a CD4- 
CD8- phenotype (43, 44, 45, 57, 58) (and may, therefore, represent γδ lymphomas), and 
CD8+ CD4- (43, 59, 60) (therefore representing aggressive epidermotropic cutaneous CD8+ 
lymphoma). 
 
The two patients that presented with more limited tumorous facial lesions had an 
appearance that resembled extranodal NK/T-cell lymphoma and blastic plasmacytoid 
dendritic cell neoplasm. Both are readily excluded by the immunophenotype; in particular, 
the absence of EBV expression is an exceptional event, if seen at all, in NK/T-cell disease. A 
single case of aggressive epidermotropic CD8+ lymphoma mimicking extranodal NK/T-cell 
lymphoma has been previously reported (46). In one patient there were more widespread 
plaques on the trunk, and there was subsequent rapid development of multiple plaques and 
tumours in the other patient. 
Recently, a report of two cases and review of the literature by Nofal et al, proposed 
diagnostic criteria for aggressive epidermotropic CD8+ cutaneous lymphoma (47). Our data 
support many of the suggested criteria; for diagnosis, we emphasise the acute presentation of 
plaques/tumours, often ulcerated/haemorrhagic, mucosal involvement is not rare; 
histologically, the finding of a pagetoid reticulosis pattern of epidermotropism, and 
angiocentricity, together with a CD8+ CD45RA+ phenotype, Ki-67 > 75%; either CD56(-) or 
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betaF1+, and expression of one or more of TIA-1 or granzyme B.  Whilst not a constant 
finding, focal or complete loss of one of CD2 or CD5 is also common; previous reports have 
documented a similar pattern. Proposed diagnostic criteria are listed in table 4. 
 
 Cutaneous lymphomas should be considered, in terms of diagnosis and management, 
on the collective bases of clinical appearance, pathological findings and immunophenotype 
rather than any of these parameters in isolation. It is the view of the workshop panel that, on 
current evidence, aggressive epidermotropic CD8+ lymphoma has a recognisable clinical 
presentation, histopathology and immunphenotype, and should be classified as a specific 
lymphoma in future revisions of the WHO lymphoma classification. Finally, in view of the 
very poor prognosis, a multicentre clinical trial using aggressive therapy might be considered 
in the future to try & improve survival for patients with this disease. 
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Table 1.Antibodies used for immunophenotyping. 
 
Antibody specificity   Species & type Clone  Source 
 Conditions 
 
CD2     Mouse IgG1  AB75  Novocastra 
 EDTA; 1/40 
CD3     Rabbit, monoclonal 2GV6  Ventana 
 EDTA; pre-diluted 
CD4     Rabbit, polyclonal SP35  Ventana 
 EDTA; pre-diluted 
CD5     Mouse, IgG1  4C7  Novocastra 
 EDTA; 1/50 dilution 
CD8     Rabbit, monoclonal SP57  Ventana 
 EDTA; pre-diluted 
CD7     Mouse, IgG2b  LP15  Novocastra 
 EDTA; 1/20 
CD45RO    Mouse, IgG2A UCHL-1 BioGenex 
 1/200 
CD45RA    Mouse, IgG1  4KB5  DakoCytomation
 1/50; citrate  
CD56     Mouse, IgG1  1B6  Novocastra 
 EDTA; 1/50    
TIA-1     Mouse, IgG1  2G9A10F5 Beckman Coulter
 1/200; citrate 
Granzyme B    Mouse, IgG2A 11F1  Novocastra 
 1/30; citrate 
BetaF1    Mouse, IgG1  8A3  ThermoScientific
 1/15; trypsin 
MIB-1     Mouse, IgG1  MIB-1  DakoCytomation
 1/5; citrate 
 
 
Table 2 Cases of Mycosis fungoides, Lymphomatoid papulosis and Pagetoid Reticulosis with a CD8+ 
phenotype 
 
 Age/sex  Clinical features    Therapy  Outcome
 Time period* Diagnosis  
 
 
54 male  patches buttocks 35 years   Chemo  A+D  48 
months MF  
 19 male  papules on limbs    DXT  A+W  68 
months MF 
 42 male  erythematosus lesions buttock  DXT  A+W  72 
months MF 
 74 male  purpura legs    NK  A+D  22 
months MF  
 26 female 10 patches hips/arms   Topical   A+D  22 
months MF 
 31 male  scaly papules    PUVA  A+D  36 
months MF 
 56 female erythematous papules   Chemo  A+W  12 
months MF 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 23 female petechial patches    DXT  A+D  120 
months MF  
 39 female poikiloderma, sacral tumour  DXT, PUVA A+D  47 
months MF 
 52 male  poikiloderma, plaques   Chemo/DXT  A+D  180 
months MF 
 40 male  erythrodermic, HIV+   Chemotherapy Died of disease 7 
months Erythrodermic MF 
 58 female erythematous hyperkeratotic lesions Chemotherapy Unknown NA
  MF 
 55 female psoriasioform patches/plaques  PUVA, Chemo  Died of disease 132 
months MF 
 60 male  eczematous lesions – plaques/nodules PUVA, retinoids A+D   120 
months MF 
 30 male  poikilodermatous scaly lesions  PUVA, Chemo A+D  132 
months MF 
 89 male  psoriasioform patches   NR  A+D   16 
months MF 
 50 female atrophic patches buttocks   UVB  A+D  72 
months MF 
 30 female erythematous scaly patches  PUVA  A+W  30 
months MF 
 43 female atropic patch buttock   DXT  A+W  42 
months MF 
 51 male  patches buttock/hip   local steroids A+D  60 
months MF 
 49 male  generalised patches   PUVA  A+W  120 
months MF 
 51 male  patches on back    PUVA  A+D  360 
months MF 
 44 male  atropic patches arms/legs   PUVA  A+W  43 
months MF 
 39 female generalised patches   PUVA  A+D  40 
months MF 
 69 male  patches axillae/groins   PUVA  A+W  11 
months MF 
 82 male  scalp erosions, plaques, nodules  DXT  A+D  36 
months MF 
 65 male  patches and plaques   Steroids  A+D  49 
months MF 
 46 male  scaly patches    PUVA  A+D  72 
months MF 
 52 female Widespread patches   PUVA  A+D  36 
months MF 
 62 male  poikiloderma    PUVA  A+D  24 
months MF 
 56 female patch on thigh    topical   A+W  36 
months MF 
 46 female psoriasioform patches,plaque arms  DXT  A+D  36 
months MF 
 55 female generalised patches   PUVA, DXT A+D  72 
months MF 
 50 male  patches/plaques    Many therapies A+D  72 
months MF 
 
 51 male  ulceronecrotic lesions arm/leg  local steroids A+W  34 
months LyP 
 38 male  ulceronecrotic lesions arm/hip  -  A+W  10 
months LyP 
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 24 female self-healing papulonodular lesions  -  A+W  120 
months Ly 
 72 female 2 papulonecrotic lesions   Excision  A+W  30 
months LyP/ALCL 
 17 female exudative nodules face,chest  Steroids  NK  NA
  LyP 
 43 male  ulcerated nodule + papule buttock  Excision  A+W  24 
months LyP 
 29 female relapsing papules/nodules    UVB  A+W  72 
months LyP 
 
 61 male  solitary gluteal lesion   Excision  A+W  24 
months Woringer-Kolopp 
 46 female solitary erythematous plaque  DXT  A+W  30 
months Woringer-Kolopp 
 
A&D = alive with disease; A&W = alive and well;  NK – not known; NA = not applicable. 
 
 
Table 3a Primary Cutaneous Aggressive Epidermotropic CD8+ Lymphoma 
 
 
Case Age/sex   Clinical features   Staging  Therapy   Outcome 
 Time period* Diagnosis  
 
1 43 male  6 weeks widespread ulcerated lesions N***  Chemotherapy Died of disease
 7 months  Aggressive epidermotropic 
2 32 male  3/12 ulcerated tumours trunk/extremities N  Chemotherapy A+ D  
 22 months  Aggressive epidermotropic 
3 NK/ male  disseminated ulcerated tumours  N  Chemotherapy Died of disease
 12 months  Aggressive epidermotropic 
4 27 female  plaques/nodules   ND  DXT  Died of disease
 84 months  Aggressive epidermotropic 
5 58 female  disseminated  plaques/nodules  N  PUVA, Chemo Died of disease
 12 months  Aggressive epidermotropic 
6 80 female  patches/plaques - papules/nodules N  PUVA/IFN Died other 
causes NA   Aggressive epidermotropic 
7 53 male  nodules arm/face/chest  N**  PUVA/DXT Died of disease
 27 months  Aggressive epidermotropic 
8 70 female  papulunecrotic tumours face/trunk N**  Chemotherapy/DXT Died of disease
 36 months  Aggressive epidermotropic 
9 87 female  haemorrhagic tumour orbit  N  IFN  Died of disease
 11 months  Aggressive epidermotropic 
10 33 male  ulcerated patches,plaques, nodules N  Chemotherapy Died of disease
 10 months  Aggressive epidermotropic 
11 31 male  palaques/nodules   N**  PUVA, Chemo, BXT Died of disease
 24 months  Aggressive epidermotropic 
12 59 male  erosive plaques   N  HN2  Died of disease
 28 months  Aggressive epidermotropic 
13 55 female  necrotic tumour elbow  N  DXT  A+W 
 43 months  Aggressive epidermotropic  
14 27 male  generalised ulcerated nodules/tumours LN+  Chemotherapy Died of disease
 7 months  Aggressive epidermotropic 
15 72 male  ulcerating tumour elbow  N  DXT  Died of disease
 10 months  Aggressive epidermotropic 
16 39 female  ulcerating tumour ear   N  DXT  Died of disease
 66 months  Aggressive epidermotropic 
17 67 male  ulcerating tumours legs  N  Chemotherapy Died of disease
 6 months  Aggressive epidermotropic 
18 74 male  ulcerated nodules leg/trunk  N  IFN, Chemo Died of disease
 12 months  Aggressive epidermotropic 
 
*From diagnosis to listed outcome. 
NA – not applicable ND not done NK not known 
DXT – radiotherapy, IFN – interferon chemotherapy, BXT – bone marrow transplantation 
N – negative, LN + lymph node enlargement  
** - developed systemic disease *** - autopsy revealed only cutaneous disease 
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Table 3b Immunophenotype of Primary Cutaneous Aggressive Epidermotropic CD8+ Lymphoma cases* 
 
Case CD 2 CD5 CD7 CD45RO CD45RA MIB-1 Beta-F1    
 
1 - +/- - +/-  +  + + 
2 +/- + - ND  ND  +++ + 
3 - + - +/-  +  + -  
4 - - - ND  ND  +++ ND 
5 - + + -  +  ++ +  
6 - - + -  +  +++ +  
7 ND ND + ND  +  +++ + 
8 - - - -  +  +++ -** 
9 + - + -  +  ++ +**  
10 - - - -  +  +++ +  
11 - - + -  +  ++ + 
12 + + ND -  +/-  ND ND 
13  - - - -  +/-  +++ ND 
14 + + - +  +  +++ ND** 
15 - - + -  +  +++ ND 
16 - - + -  +  + ND 
17 - - - ND  -  ND ND 
18 ND ND - -  +  +++ ND 
 
*All cases were CD8+, CD4-. None labelled with CD56 or antibodies to LMP, and all were negative with in-
situ hybridisation for EBER. 
T-cell antigens: 
+ = at least 75% cells positive 
- = less than 10% cells positive 
+/- = between 10-75% cells positive 
MIB-1: 
+ = 25-50% 
++ = 50-75% 
+++= >75% 
** Immunohistochemically negative for T-cell receptor δ on frozen section. 
All cases demonstrated T-cell clonality by analysis of T-cell receptor. 
 
 
 
Table 4 Proposed diagnostic criteria for the diagnosis of Primary Cutaneous Aggressive Epidermotropic 
CD8+ Lymphoma 
 
Clinical features   Histology   Immunohistochemistry 
 
 
Plaques and tumours  Pagetoid reticulosis pattern CD8+ CD56(-) 
No history of patches,   +/- apoptotic keratinocytes At least 1 of CD2(-), CD5(-) or  
evidence of follicular       CD45RA(+) 
mucinosis or poikiloderma  Monomorphic atypia  Ki-67> 50%  
        BetaF1(+) or TCR δ(-) 
Staging confirms only       EBER(-) 
cutaneous disease 
 
No immunosuppression 
 
 
 
 
 
